JP2020519687A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519687A5
JP2020519687A5 JP2020512769A JP2020512769A JP2020519687A5 JP 2020519687 A5 JP2020519687 A5 JP 2020519687A5 JP 2020512769 A JP2020512769 A JP 2020512769A JP 2020512769 A JP2020512769 A JP 2020512769A JP 2020519687 A5 JP2020519687 A5 JP 2020519687A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
pharmaceutically acceptable
optionally
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512769A
Other languages
English (en)
Japanese (ja)
Other versions
JP7058322B2 (ja
JP2020519687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031593 external-priority patent/WO2018208769A1/en
Publication of JP2020519687A publication Critical patent/JP2020519687A/ja
Publication of JP2020519687A5 publication Critical patent/JP2020519687A5/ja
Application granted granted Critical
Publication of JP7058322B2 publication Critical patent/JP7058322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512769A 2017-05-08 2018-05-08 細菌感染症を治療するための化合物および方法 Active JP7058322B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
US62/502,867 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (3)

Publication Number Publication Date
JP2020519687A JP2020519687A (ja) 2020-07-02
JP2020519687A5 true JP2020519687A5 (enExample) 2021-06-10
JP7058322B2 JP7058322B2 (ja) 2022-04-21

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512769A Active JP7058322B2 (ja) 2017-05-08 2018-05-08 細菌感染症を治療するための化合物および方法

Country Status (27)

Country Link
US (1) US11046694B2 (enExample)
EP (1) EP3630111B1 (enExample)
JP (1) JP7058322B2 (enExample)
KR (1) KR102611447B1 (enExample)
CN (1) CN110709081B (enExample)
AU (1) AU2018266640B2 (enExample)
CA (1) CA3059773A1 (enExample)
CY (1) CY1125340T1 (enExample)
DK (1) DK3630111T3 (enExample)
EA (1) EA038393B1 (enExample)
ES (1) ES2907858T3 (enExample)
HR (1) HRP20220231T1 (enExample)
HU (1) HUE057592T2 (enExample)
IL (1) IL270380B (enExample)
LT (1) LT3630111T (enExample)
MA (1) MA48743A (enExample)
MX (1) MX385203B (enExample)
MY (1) MY201377A (enExample)
PE (1) PE20200333A1 (enExample)
PH (1) PH12019502509A1 (enExample)
PL (1) PL3630111T3 (enExample)
PT (1) PT3630111T (enExample)
SG (1) SG11201909443YA (enExample)
SI (1) SI3630111T1 (enExample)
SM (1) SMT202200110T1 (enExample)
TW (1) TWI791018B (enExample)
WO (1) WO2018208769A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3833665T3 (da) 2018-08-09 2023-10-09 Antabio Sas Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
EP4146651A4 (en) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2025064681A1 (en) * 2023-09-19 2025-03-27 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018129A1 (en) 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2135959A1 (en) 2008-06-19 2009-12-23 Novexel Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2011373912B2 (en) 2011-07-26 2016-09-29 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
JP5808860B2 (ja) 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
RU2636147C1 (ru) 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
AU2012303693B2 (en) * 2011-08-30 2014-07-03 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections
US8754102B2 (en) 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AU2013237869A1 (en) 2012-03-30 2014-10-23 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2013149121A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
TWI565707B (zh) 2012-05-30 2017-01-11 明治製菓藥業股份有限公司 新穎β-內醯胺酶抑制劑及其製造方法
EP2961751B1 (en) 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
CN104768547A (zh) 2012-09-03 2015-07-08 沃克哈特有限公司 抗菌组合物
CA2897446A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US9968593B2 (en) 2014-11-17 2018-05-15 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
SMT202200397T1 (it) 2016-09-16 2022-11-18 Entasis Therapeutics Ltd Composti inibitori di beta-lattamasi

Similar Documents

Publication Publication Date Title
JP2020519687A5 (enExample)
JP2019513778A5 (enExample)
JP2014525420A5 (enExample)
JP2016506960A5 (enExample)
JP2013544276A5 (enExample)
JP2016503799A5 (enExample)
JP2016506962A5 (enExample)
JP2009534386A5 (enExample)
JP2016505586A5 (enExample)
JP2018516904A5 (enExample)
JP2016515561A5 (enExample)
JP2010511721A5 (enExample)
JP2016507575A5 (enExample)
JP2013531029A5 (enExample)
JP2018524406A5 (enExample)
JP2007524696A5 (enExample)
JP2020097577A5 (enExample)
JP2010527913A5 (enExample)
JP2012513416A5 (enExample)
JP2014510147A5 (enExample)
JP2020122016A5 (enExample)
JP2015516427A5 (enExample)
JP2012530765A5 (enExample)
JP2017517565A5 (enExample)
JP2016531126A5 (enExample)